I-BASE HIV TREATMENT BULLETINImportant note: Information in this article was accurate in March 2007. The state of the art may have changed since the publication date.
Click here to return to I-BASE main menu
DonateNow

FDA approval of generic ARVs

HIV Treatment Bulletin - Vol. 8, No. 11&12, November/December 2007


Since the last issue of HTB, the US Food and Drug Administration (FDA) has granted tentative approval for the following new generic ARV products.

Date

Drug

Company

30 November 2007

Tenofovir DF (300mg)

Matrix, India

29 November 2007

AZT/3TC (300/150 mg)

Matrix, India

2 November 2007

d4T/3TC (40/150mg and 30/150mg)

Matrix, India

29 October 2007

d4T oral solution

Cipla, India

“Tentative Approval” means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but because of existing patents and/or exclusivity rights, it cannot yet be marketed in the United States. Tentative approval does, however make the product eligible for consideration for purchase under the PEPFAR program for use outside the United States.

Effective patent dates are listed in the agency’s publication titled,

Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the “Orange Book"

comment

Of this expanding list, this is the first approval of tenofovir, which will enable both more tolerable first-line and more effective second-line options. This brings the total of FDA approved generic drugs and formulations to 51 since the programme started.

An updated list of generic tentative approvals is included as a table on the i-Base website: http://www.i-base.info/itpc/fdageneric.html

Source: FDA list serve

A list of FDA approved generic antiretroviral drugs for the treatment of HIV is available on the web atOpen link in new window http://www.fda.gov/oashi/aids/viralsgeneric.html

2008-11-01
IB070811-09


©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.